The emerging role of non-coding RNAs in the Wnt/ß-catenin signaling pathway in Prostate Cancer.

Prostate cancer (PCa) is an important worldwide medical concern, necessitating a greater understanding of the molecular processes driving its development. The Wnt/-catenin signaling cascade is established as a central player in PCa pathogenesis, and recent research emphasizes the critical involvement of non-coding RNAs (ncRNAs) in this scenario. This in-depth study seeks to give a thorough examination of the complex relationship between ncRNAs and the Wnt/ß-catenin system in PCa. NcRNAs, such as circular RNAs (circRNAs), long ncRNAs (lncRNAs), and microRNAs (miRNAs), have been recognized as essential regulators that modulate numerous facets of the Wnt/ß-catenin network. MiRNAs have been recognized as targeting vital elements of the process, either enhancing or inhibiting signaling, depending on their specific roles and targets. LncRNAs participate in fine-tuning the Wnt/ß-catenin network as a result of complicated interplay with both upstream and downstream elements. CircRNAs, despite being a relatively recent addition to the ncRNA family, have been implicated in PCa, influencing the Wnt/ß-catenin cascade through diverse mechanisms. This article encompasses recent advances in our comprehension of specific ncRNAs that participate in the Wnt/ß-catenin network, their functional roles, and clinical relevance in PCa. We investigate their use as screening and predictive indicators, and targets for treatment. Additionally, we delve into the interplay between Wnt/ß-catenin and other signaling networks in PCa and the role of ncRNAs within this complex network. As we unveil the intricate regulatory functions of ncRNAs in the Wnt/ß-catenin cascade in PCa, we gain valuable insights into the disease's pathogenesis. The implementation of these discoveries in practical applications holds promise for more precise diagnosis, prognosis, and targeted therapeutic approaches, ultimately enhancing the care of PCa patients. This comprehensive review underscores the evolving landscape of ncRNA research in PCa and the potential for innovative interventions in the battle against this formidable malignancy.

Review of the potential pharmacological role of erucic acid: a monounsaturated omega-9 fatty acid.

This comprehensive review aims to provide an overview of the pharmacological properties of erucic acid (EA) and highlight areas that require further research. EA is an omega-9 fatty acid found in certain vegetable oil, such as rapeseed oil has demonstrated favourable effects in rodents, including ameliorating myocardial lipidosis (fat accumulation in the heart muscle), congestive heart disease, hepatic steatosis (fat accumulation in the liver), and memory impairments. These findings have prompted regulatory bodies to establish limits on EA content in food oils. The studies were performed on rodents and led to caution on ingesting the EA at high levels. Moreover, EA is frequently utilized as a nutritional supplement for the treatment of adrenoleukodystrophy, myocardial disease, and memory improvement. The review of the article indicated that EA improves cognitive function, has a part in Huntington's disease, interacts with peroxisome proliferator-activated receptors, inhibits elastase and thrombin, has anti-inflammatory, antioxidant, and anti-tumour properties, and inhibits influenza A virus. This article elucidates the pharmacological effects of EA, an omega-9 fatty acid.

Comparison of quality of life in children undergoing peritoneal dialysis versus hemodialysis.

OBJECTIVES: To record pediatric end stage renal disease (ESRD) patients' quality of life (QOL) in relation to peritoneal dialysis (PD) and hemodialysis (HD). Chronic kidney disease is a rising global epidemic yielding worldwide prevalence of 11-13%. It could possibly lead to ESRD, thus imposing serious burdens on patients and reducing their QOL. These burdens may affect their family members as well. Methods: This cross-sectional study examined 23 pediatric ESRD patients aged 2-18 years who were undergoing peritoneal dialysis and hemodialysis at King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia, in July 2018. Data were collected using the validated Pediatric Quality of Life InventoryTM 3.0 ESRD Module questionnaire. Results: The sample included HD (n=9, 40.9%) and PD (n=14, 60.9%) patients. According to the parent-proxy report, we found that the QOL among PD pediatric patients was significantly higher than HD patients (p=0.045). Also, male HD patients had a significantly better QOL on the interaction subscale (70.83±15.95 compared to 30.00±24.00 for females [p=0.023]). Conclusion:   Quality of life was found to be better among PD pediatric patients in King Abdulaziz University Hospital, Kingdom of Saudi Arabia.